RAGE anticorps (AA 24-52)

N° du produit ABIN7872703

Cet anticorps anti-RAGE Polyclonal Lapin (ABIN7872703) détecte spécifiquement RAGE dans WB, FACS et IHC (p). L’anticorps est réactif avec des échantillons de Humain et Souris.

Aperçu rapide pour RAGE anticorps (AA 24-52) (ABIN7872703)

Antigène: RAGE (AGER) (Advanced Glycosylation End Product-Specific Receptor (AGER))

Reactivité: Humain, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp RAGE est non-conjugé

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Détail du produit anti-RAGE anticorps

Épitope: AA 24-52

Fonction: AGER Antibody / RAGE

Purification: Antigen affinity

Immunogène: A portion of amino acids 24-52 from the human protein was used as the immunogen for this AGER antibody.

Isotype: Ig Fraction

Information d'application

Indications d'application: The stated application concentrations are suggested starting amounts. Titration of the AGER antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4oC for up to one month. For long term, aliquot the AGER antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur RAGE

Antigène: RAGE (AGER) (Advanced Glycosylation End Product-Specific Receptor (AGER))

Autre désignation: AGER

Sujet: AGER is a cell surface receptor that is specifically activated by AGEs, which are formed when sugars react non-enzymatically with proteins or lipids. These AGEs are known to accumulate in various tissues over time, contributing to the development of complications like diabetic nephropathy, retinopathy, and neuropathy. AGER acts as a receptor for these AGEs, signaling pathways that lead to inflammation, oxidative stress, and tissue damage. Understanding the role of AGER in diabetes-related complications has significant implications for the development of novel therapeutic strategies. By targeting AGER and its downstream signaling pathways, researchers hope to mitigate the harmful effects of AGE accumulation in diabetic patients. In fact, recent studies have shown that blocking AGER with specific inhibitors can reduce inflammation and oxidative stress in diabetic animal models, offering promise for future treatments. In addition to its role in diabetes, AGER has also been implicated in other age-related diseases, such as Alzheimer's and cardiovascular disease. By studying the mechanisms by which AGER mediates these diseases, researchers can gain valuable insights into the underlying pathophysiology and identify new targets for intervention.

UniProt: Q15109

Pathways: Carbohydrate Homeostasis, Toll-Like Receptors Cascades, Smooth Muscle Cell Migration, S100 Proteins